Harmony Biosciences Holdings Earnings Call Transcripts
Fiscal Year 2026
-
Strong WAKIX growth and expanded sales teams support a $1B+ revenue target, while new pitolisant formulations and a potent orexin program drive pipeline expansion. Settlements secure exclusivity, and robust cash reserves enable strategic business development across CNS indications.
-
Momentum into 2026 is driven by WAKIX's blockbuster trajectory, a robust late-stage CNS pipeline, and strong financials. Key milestones include multiple phase III readouts, NDA submissions, and commercial expansion, with significant market opportunity and capital for further growth.
Fiscal Year 2025
-
Q4 2025 saw record revenue growth and strong WAKIX adoption, with blockbuster guidance for 2026. Pipeline progress, pediatric approval, and robust cash position support continued expansion, while settlements delay generic entry to 2030 if pediatric exclusivity is granted.
-
WAKIX continues robust growth with record patient adds, driven by improved execution and payer access. The narcolepsy market is expanding, and WAKIX is well-positioned amid upcoming generic and orexin competition. Next-gen pitolisant and clemizole programs advance, targeting broader indications and improved safety.
-
Wakix continues to drive strong patient and revenue growth, supported by new formulations and a robust pipeline including orexin-2 agonists and EPX-100. Organizational expansion and business development are focused on scaling for multiple late-stage programs and commercial opportunities.
-
Q3 2025 saw record revenue and patient growth, with WAKIX net sales up 29% year-over-year and full-year guidance raised to $845–$865 million. Strong cash generation supports a robust late-stage pipeline, while strategic capital deployment and product differentiation position the company for continued growth.
-
Leadership highlighted a robust late-stage pipeline with key programs in Fragile X, narcolepsy, and rare epilepsies. ZYN002 is nearing a pivotal data readout, while Wakix continues strong commercial growth and next-gen formulations advance.
-
Q2 2025 net revenue grew 16% year-over-year to $202.5M, driven by WAKIX's strong performance and patient growth. The late-stage pipeline advanced with key catalysts ahead, and full-year revenue guidance of $820M–$860M was reaffirmed.
-
Strong commercial growth is driven by Wakix, with next-generation formulations and a robust late-stage pipeline targeting rare CNS disorders. ZYN002 and EPX100 are key near-term catalysts, while strategic capital allocation supports ongoing innovation and business development.
-
A robust late-stage pipeline in orphan CNS diseases is set to deliver up to two launches annually, with strong commercial growth in narcolepsy and new formulations targeting unmet needs. Recent acquisitions and patent settlements extend exclusivity, while a strong balance sheet supports further expansion.
-
Q1 2025 saw 20% revenue and 19% net income growth, driven by WAKIX's strong demand and expanding market penetration. The late-stage pipeline advanced with multiple Phase III trials, and guidance for 2025 revenue was reiterated at $820–$860 million, supported by a robust balance sheet.
-
A robust, profitable biotech highlighted its late-stage, catalyst-rich CNS pipeline, with major phase III data for Fragile X syndrome expected in Q3 2024 and next-generation product launches planned for 2026 and 2028. Strategic capital deployment and a strong safety/efficacy profile underpin growth.
-
A robust late-stage pipeline targets rare CNS disorders, with ZYN002 for Fragile X and EPX-100 for rare epilepsies advancing in phase three. WAKIX continues strong commercial growth, and next-generation narcolepsy therapies are in development. Over $576 million in cash supports ongoing expansion.
-
Entering 2025 with a robust late-stage pipeline and strong financials, the company expects key clinical and regulatory catalysts each quarter, including potential new indications and product launches. WAKIX continues to drive growth, while innovation and strategic business development support long-term value creation.
Fiscal Year 2024
-
Delivered 23% year-over-year revenue growth in 2024, with Wakix net sales surpassing $700 million and strong profitability. Advanced late-stage CNS pipeline, settled first generic litigation, and guided 2025 revenues to $820–$860 million.
-
Q3 2024 saw strong revenue growth and pipeline advancement, with WAKIX net sales reaching $186M and cumulative sales surpassing $2B. The company reiterated 2024 guidance of $700–$720M, highlighted robust late-stage CNS programs, and maintained a strong cash position of $504.7M.
-
A diversified late-stage pipeline in rare CNS diseases is set to deliver one or more new launches annually over the next five years, with WAKIX driving near-term growth and innovative lifecycle management extending revenue into the 2040s. The company remains profitable and self-funding, with all programs fully financed by strong cash flows.
-
The company is leveraging strong financials and a differentiated narcolepsy drug to drive growth, with a robust pipeline targeting sleep-wake, epilepsy, and neurobehavioral disorders. Key near-term catalysts include an sNDA for idiopathic hypersomnia and multiple phase III readouts.
-
A robust late-stage pipeline, strong commercial growth in narcolepsy, and recent pediatric approval position the company for continued expansion. Upcoming catalysts include an sNDA submission for idiopathic hypersomnia and phase 3 data for Fragile X syndrome, supported by a solid financial base.
-
Q2 saw 29% year-over-year revenue growth, strong WAKIX adoption, and expanded pipeline progress. Patent protection was reinforced, pediatric approval launched, and 2024 guidance was reiterated, with a clear path to $1B in sales by 2030.
-
WAKIX continues robust double-digit growth, outperforming historical analogs and maintaining strong market position despite generic competition. Pipeline advances include sNDA submission for IH, next-gen pitolisant programs, and strategic acquisitions in orexin-2 agonists, epilepsy, and Fragile X syndrome.